Chief Financial Officer update
Chief Financial Officer update
December 8, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, announced on August 21, 2017, that Jeff Poulton, Chief Financial Officer, would leave Shire at the end of the year. On November 20, 2017, Shire announced that Thomas Dittrich will join the company as Chief Financial Officer in early 2018.
Shire today announces that Jeff Poulton will leave on December 31, 2017, and John Miller, Shire’s Senior Vice President of Finance, will be appointed Interim Chief Financial Officer with effect from January 1, 2018, until Mr. Dittrich commences his employment with Shire.
Mr. Miller joined Shire in 2004 and, in addition to his current role in which he has served since March 2015, has served in a number of positions including, in the past five years, as Vice President of Finance, Neuroscience from June 2010 to March 2015.
For further information please contact:
| Investors | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 203 549 0874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Katie Joyce | [email protected] | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.